Boots launches £99-a-year medical cannabis online prescribing service
In Business
Follow this topic
Bookmark
Record learning outcomes
Boots Online Doctor has launched a private medical cannabis service for adults with some long-term conditions such as chronic pain, generalised anxiety disorder and insomnia.
The service, which is called Sureleaf, is priced at £99 a year. This covers an initial assessment and four follow-up consultations, with treatment and any additional appointments priced separately. A one-month trial including an assessment and a 10ml ‘starter dose’ of cannabis oil is also available for £89.
The service is available to adults aged 25 or over who have tried at least two conventional treatments such as prescription drugs or psychotherapy before considering cannabis, with an online questionnaire used initially to screen out those patients who have not yet done so.
Online assessments are followed by an in-house clinical suitability review before progressing to a video consultation with a consultant in a relevant medical specialty who is on the General Medical Council’s specialist register.
A second consultant carries out an independent review before any prescriptions are issued, said Boots, adding that patients will be reviewed at least once every three months to assess any impact on pain, anxiety, sleep and mood.
“Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis,” said Boots Online Doctor medical director Dr David Gwynne, adding that “strong safeguards” are built into the service.
Jamie Kerruish, chief healthcare officer at Boots, said: “Millions of people live with ongoing pain and for some, conventional treatments do not provide adequate symptom relief. This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy.
“Medical cannabis is a specialist area of healthcare and, through SureLeaf, we’re giving eligible patients another treatment option to consider, supported by clinical expertise and robust ongoing care.”
Boot said that in order to help establish an evidence base on the use of medical cannabis, it is exploring a possible research project with the University of Nottingham to assess patient outcomes from the service, as well as prescribing practices and “experience in the treatment of chronic pain”.
Related: Irish CBD product first to gain food supplement approval